Details:
The grant will support the Phase III registrational study of ELGN-GI (recombinant human insulin), an innovative oral formulation for the treatment of intestinal malabsorption, that causes feeding intolerance in preterm infants.
Lead Product(s): Recombinant Human Insulin
Therapeutic Area: Gastroenterology Product Name: ELGN-GI
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: European Innovation Council
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 19, 2023
Details:
Bekinda (formerly known as RHB-102) is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications.
Lead Product(s): CAS 103639-04-9
Therapeutic Area: Gastroenterology Product Name: Bekinda
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Bekinda (RHB-102) is a proprietary, oral, bi-modal extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron.
Lead Product(s): CAS 103639-04-9
Therapeutic Area: Gastroenterology Product Name: Bekinda
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
Study result for ELGN-GI, indicate improvement in GI function and, reduction in complication, include reduction in time until life threatening central line can be removed, reduction in hospital stay, and reduction in number of life-threatening necrotizing enterocolitis events.
Lead Product(s): Recombinant Human Insulin
Therapeutic Area: Gastroenterology Product Name: ELGN-GI
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035. Opaganib also undergoing two oncology Phase 2 U.S. studies as well as several development programs for inflammatory and viral indications, including Ebola.
Lead Product(s): Clarithromycin,Rifabutin,Clofazimine
Therapeutic Area: Gastroenterology Product Name: RHB-104
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.
Lead Product(s): Clarithromycin,Rifabutin,Clofazimine
Therapeutic Area: Gastroenterology Product Name: RHB-104
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 01, 2021
Details:
The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.
Lead Product(s): Clarithromycin,Rifabutin,Clofazimine
Therapeutic Area: Gastroenterology Product Name: RHB-204
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2021